Literature DB >> 17922883

Relative lung deposition of salbutamol following inhalation from a spacer and a Sidestream jet nebulizer following an acute exacerbation.

Syed H R Mazhar1, Nahlah E Ismail, Duncan A G Newton, Henry Chrystyn.   

Abstract

UNLABELLED: What is already known about this subject. Studies have shown that a large volume spacer attached to a metered dose inhaler provides similar bronchodilator effects to nebulized dosing during the management of patients following an acute exacerbation. Due to the high doses used, these effects could be measured at the top of the dose-response relationship and the response limited due to the patient's exacerbation. Although clinical end-points are the gold standard to show comparability, some indication of similar lung deposition is useful to consolidate any claims. What this study adds. The urinary pharmacokinetic method we have used postinhalation provides an index of lung deposition for inhalation methods that can be incorporated into the routine management of patients with an acute exacerbation. This is the first study to identify and compare lung deposition and systemic delivery for inhalation methods within the setting of the routine management of asthma and chronic obstructive pulmonary disease patients following hospitalization due to an acute exacerbation. The study highlights the comparability of the doses for the two inhalation methods evaluated with respect to lung deposition, systemic delivery and bronchodilator response.
BACKGROUND: Studies comparing inhalation methods in acute exacerbations have not assessed lung deposition.
METHODS: Five 100-mug salbutamol doses were inhaled from a metered dose inhaler plus spacer (MDI + SP) and 5 mg was nebulized (NEB) following acute exacerbation hospitalization. Urinary salbutamol excretion was determined at 30 min (USAL0.5) and over 24 h (USAL24) postinhalation together with forced expiratory volume in 1 s (FEV(1)).
RESULTS: The USAL0.5 mean ratio (90% confidence interval) post MDI + SP and NEB [n = 19 asthma, 11 chronic obstructive pulmonary disease (COPD)] was 1.01 (0.81, 1.26). USAL24 was less (P < 0.001) following MDI + SP, whereas FEV(1) was similar. Only a small difference between asthmatics and COPD patients was observed for the MDI + SP in that the USAL0.5 was higher in the asthmatics for the spacer method.
CONCLUSION: The relative lung deposition after inhaling 500 mug salbutamol from MDI + SP is similar to 5 mg from a Sidestream nebulizer following an acute exacerbation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922883      PMCID: PMC2291256          DOI: 10.1111/j.1365-2125.2007.03036.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  European Respiratory Society Guidelines on the use of nebulizers.

Authors:  J Boe; J H Dennis; B R O'Driscoll; T T Bauer; M Carone; B Dautzenberg; P Diot; K Heslop; L Lannefors
Journal:  Eur Respir J       Date:  2001-07       Impact factor: 16.671

2.  Determination of the relative bioavailability of salbutamol to the lung following inhalation.

Authors:  M Hindle; H Chrystyn
Journal:  Br J Clin Pharmacol       Date:  1992-10       Impact factor: 4.335

3.  Effects of airway calibre on lung delivery of nebulised salbutamol.

Authors:  B J Lipworth; D J Clark
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

4.  Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol.

Authors:  D J Clark; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1996-03       Impact factor: 4.335

Review 5.  Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.

Authors:  D Brocklebank; F Ram; J Wright; P Barry; C Cates; L Davies; G Douglas; M Muers; D Smith; J White
Journal:  Health Technol Assess       Date:  2001       Impact factor: 4.014

  5 in total
  7 in total

1.  Pharmacokinetic(s) matters: stroke treatment et cetera.

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2008-03       Impact factor: 4.335

2.  The interaction between the oropharyngeal geometry and aerosols via pressurised metered dose inhalers.

Authors:  T Ehtezazi; I Saleem; I Shrubb; D R Allanson; I D Jenkinson; C O'Callaghan
Journal:  Pharm Res       Date:  2009-11-10       Impact factor: 4.200

3.  Mass spectrometry detection of inhaled drug in distal fibrotic lung.

Authors:  Peter Marshall; Joanna C Porter; Theresia A Mikolasch; Eunice Oballa; Mitra Vahdati-Bolouri; Emily Jarvis; Yi Cui; Anthony Cahn; Rebecca L Terry; Jagdeep Sahota; Ricky Thakrar
Journal:  Respir Res       Date:  2022-05-11

Review 4.  The World Anti-Doping Code: can you have asthma and still be an elite athlete?

Authors:  Ken Fitch
Journal:  Breathe (Sheff)       Date:  2016-06

5.  Effects of flow rate on transnasal pulmonary aerosol delivery of bronchodilators via high-flow nasal cannula for patients with COPD and asthma: protocol for a randomised controlled trial.

Authors:  Jie Li; Jian Luo; Yibing Chen; Lixing Xie; James B Fink
Journal:  BMJ Open       Date:  2019-06-24       Impact factor: 2.692

Review 6.  What Can We Apply to Manage Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Acute Respiratory Failure?

Authors:  Deog Kyeom Kim; Jungsil Lee; Ju Hee Park; Kwang Ha Yoo
Journal:  Tuberc Respir Dis (Seoul)       Date:  2018-01-24

Review 7.  Acute exacerbation of COPD.

Authors:  Fanny W Ko; Ka Pang Chan; David S Hui; John R Goddard; Janet G Shaw; David W Reid; Ian A Yang
Journal:  Respirology       Date:  2016-03-30       Impact factor: 6.424

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.